Nuvation Bio (NUVB) Non-Current Deffered Revenue (2020 - 2026)

Nuvation Bio (NUVB) has reported Non-Current Deffered Revenue for 5 consecutive years, with $151.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 1015.66% year-over-year to $151.9 million; the TTM figure through Mar 2026 stood at $151.9 million (up 1015.66% YoY), while the FY2025 annual figure was $145.8 million, changed N/A from the prior year.
• Non-Current Deffered Revenue rose to $151.9 million in Q1 2026 per NUVB's latest filing, from $145.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $151.9 million in Q1 2026 and bottomed at $7.9 million in Q3 2024.
• Historically, Non-Current Deffered Revenue has averaged $88.0 million across 3 years, with a median of $142.8 million in 2025.
• Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue soared 1722.11% — and 2026, when it jumped 1015.66%.
• Nuvation Bio's Non-Current Deffered Revenue stood at $7.9 million in 2024, then soared by 1737.21% to $145.8 million in 2025, then grew by 4.16% to $151.9 million in 2026.
• Business Quant data shows NUVB's Non-Current Deffered Revenue at $151.9 million in Q1 2026, $145.8 million in Q4 2025, and $144.6 million in Q3 2025.